Navigation Links
OrbusNeich Announces First Patient Enrolled in Randomized Clinical Trial of Genous(TM) Bio-engineered R stent(TM) in China
Date:2/11/2010

HONG KONG, Feb. 11 /PRNewswire/ -- OrbusNeich today announced that the first patient has been enrolled in a randomized clinical trial of the Genous Bio-engineered R stent in China.

A multicenter, randomized, controlled study, the trial will enroll 180 patients split evenly between the control and test arms at 11 sites countrywide. The primary study objective is to demonstrate the safety and effectiveness of the Genous Bio-engineered R stent compared to the Medtronic Endeavor Sprint stent.  

The study population will consist of patients ages 18 to 75 with symptoms of angina or myocardial ischemia. The primary endpoints are difference in Major Adverse Cardiac Event (MACE) rates between the two groups at 12 months following implant and 270 day angiographic Late Loss (LL). Secondary endpoints include all-cause and cardiac mortality, myocardial infarction, in-stent thrombosis, MACE rates at 30, 60, 90, 180 and 270 days, as well as clinically driven Target Lesion Revascularization (TLR), Target Vessel Revascularization (TVR) and Target Lesion Failure (TLF) rates at 30, 60, 90, 180, 270 and 360 days.  

The first patient was enrolled in the study at Beijing Chaoyang Hospital on December 8, 2009.

"We believe that the Genous Bio-engineered R stent will provide an excellent treatment option to patients who present challenging cases with standard drug eluting stents," said Prof. Lu Shuzheng from Anzhen Hospital, principal investigator of the trial.

Al Novak, OrbusNeich's chairman and CEO, added, "We are excited to take the Genous Bio-engineered R stent into this pivotal trial in China. We expect that clinical data from this study will show positive benefits for patients, including those who
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM)
2. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Subject of Sessions on Innovation at TCT 2007
3. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
4. OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) has Lower MACE Rate than TAXUS(R) and CYPHER(R) Stents in Clinical Trial
5. Clinical Impact of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) is Subject of Symposium at 16th Annual Scientific Congress of Hong Kong College of Cardiology
6. Data from Randomized Pilot Study, Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008
7. Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents
8. Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents
9. Data From Multiple Clinical Trials of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008
10. Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
11. Long Term Data Presented at EuroPCR 2009 from Randomized Study Attest to Durability of Results of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) Compared to Drug-Eluting Stents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2015 Tumultuous market conditions – including changes ... M&A activity – have led more than half of ... sales reps. This marks the first time that the ... halfway point, according to the spring 2015 AccessMonitor™ ... ZS . AccessMonitor™ aggregates sales-call ...
(Date:9/2/2015)... 2, 2015 On Tuesday, September ... of physicians who prescribe biologics – Alliance ... Endocrinologists, American College of Rheumatology, Biologics Prescribers ... North American Society for Pediatric Gastroenterology, Hepatology ... Centers for Medicare and Medicaid Services (CMS) ...
(Date:9/2/2015)... , Sept. 2, 2015   Americord Registry , a ... placenta tissue banking company, announced today that is ... 500. Logo - http://photos.prnewswire.com/prnh/20150902/263095LOGO ... to have grown at least tenfold over the past three ... has continued this trend with 50% quarterly growth during the ...
Breaking Medicine Technology:Crossing the threshold: More than half of physicians restrict access to sales reps 2Crossing the threshold: More than half of physicians restrict access to sales reps 3Crossing the threshold: More than half of physicians restrict access to sales reps 4Crossing the threshold: More than half of physicians restrict access to sales reps 5Physician Groups Urge CMS: Follow FDA Lead on Unique Names for Biological Medicines 2Physician Groups Urge CMS: Follow FDA Lead on Unique Names for Biological Medicines 3Physician Groups Urge CMS: Follow FDA Lead on Unique Names for Biological Medicines 4Physician Groups Urge CMS: Follow FDA Lead on Unique Names for Biological Medicines 5Physician Groups Urge CMS: Follow FDA Lead on Unique Names for Biological Medicines 6Americord Registry Announces Ranking on 2015 Inc. 500 2
... Reportlinker.com announces that a new market ... Global Microscopes Industry ... This report analyzes the worldwide markets for ... Product Segments: Optical Microscopes, Charged Particle Microscopes, ...
... 2011  Tethys Bioscience has entered into an agreement with ... measurably flatten the trajectory of their healthcare trends through ... employee populations. The agreement allows ACAP Health to offer ... a component of its disease intervention programs. The PreDx ...
Cached Medicine Technology:Global Microscopes Industry 2Tethys Bioscience and ACAP Health Consulting Partner to Help Employers Prevent Diabetes 2Tethys Bioscience and ACAP Health Consulting Partner to Help Employers Prevent Diabetes 3
(Date:9/2/2015)... ... September 02, 2015 , ... The Hydration ... allopathic medicine, opens its second location this week at 31542 S. Coast Hwy, ... feet of lounge space for patients to relax while receiving safe and effective ...
(Date:9/2/2015)... Burnsville, MN (PRWEB) , ... September 02, 2015 , ... ... forward to it; others dread it. However, few are prepared to face the academic ... once school starts. Our schools haven’t prepared them since schools don’t teach students how ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... the upper extremity surgical market, announced today that more than 600 successful patient ... in the hand. Plus, nearly 70 of these procedures have been on ...
(Date:9/2/2015)... ... September 02, 2015 , ... Lakeview Health, a nationally recognized ... Overdose Awareness Day. The goal is to provide people information regarding drugs and ... they may get help. , Lakeview Health will be publishing information ...
(Date:9/2/2015)... PA (PRWEB) , ... September 02, 2015 , ... Pentec ... prestigious 2015 Inc. 5000 List for an impressive sixth consecutive year. Less than 5 ... with only twelve firms in the “health” sector. Pentec’s 3-year revenue growth rate ...
Breaking Medicine News(10 mins):Health News:The Hydration Room Opens New Location In Laguna Beach, California 2Health News:The Hydration Room Opens New Location In Laguna Beach, California 3Health News:The Hydration Room Opens New Location In Laguna Beach, California 4Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 2Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 3Health News:Trigger Tome Surpasses 600 Successful Patient Procedures 2Health News:August 31 is International Overdose Awareness Day – Lakeview Health to Help Bring Awareness 2Health News:Pentec Health Once Again Named One of the Fastest-Growing Private Companies in America 2
... Tenn., Jan. 13 The National Eczema Association,(NEA) awarded ... Lotion. , The NEA Seal ... Education (EASE) program, which is intended to improve the,quality ... eczema and sensitive,skin. , "These ...
... now open for a more rewarding challenge , ... Jenkintown, PA (PRWEB) January 13, 2009 ... resolutions and according to USA.gov, losing weight and getting fit are among the ... many of those eager to fulfill their vows is to lace up their ...
... to meet their customers, product needs quickly and efficiently, Nationwide Medical/Surgical ... 2009-2010 season beginning in August. , ... (Vocus) January ... the Flu Vaccine for the 2009-2010 flu season. ...
... persistence to seek out the best treatment options available ... leg today. Bill,s proactive efforts led him to revolutionary ... Methodist Hospital, in Columbus, Ohio, where a team of ... During the minimally invasive procedure, they also found and ...
... announces the launch of their new website www.GlaceComplete.com . ... to Glenwood Systems and the company,s turbo-charged practice management/billing system GlaceComplete ... information. , ... Waterbury, CT (PRWEB) January Monday 12, ...
... of the 21,000 Americans who die each year of ... likely cause. So, the American Association of ... Cancer Survivors Against Radon (CanSAR) with a ... those who never smoked. Those making the connection, along ...
Cached Medicine News:Health News:National Eczema Association Anoints Theraplex Child-Friendly Eczema Products with Seal of Acceptance 2Health News:The Breast Cancer 3-Day Challenges Americans to Get Out of the New Year's Resolution Rut 2Health News:The Breast Cancer 3-Day Challenges Americans to Get Out of the New Year's Resolution Rut 3Health News:The Breast Cancer 3-Day Challenges Americans to Get Out of the New Year's Resolution Rut 4Health News:Nationwide Medical/Surgical Announces They Will Carry Flu Vaccine 2Health News:Irishman with Peripheral Arterial Disease (P.A.D.) Finds Leg-, Life-Saving Treatment In Columbus, Ohio 2Health News:Irishman with Peripheral Arterial Disease (P.A.D.) Finds Leg-, Life-Saving Treatment In Columbus, Ohio 3Health News:Irishman with Peripheral Arterial Disease (P.A.D.) Finds Leg-, Life-Saving Treatment In Columbus, Ohio 4Health News:Glenwood Systems, LLC Launches New Website -- GlaceComplete.com 2Health News:Program to Identify Likely Victims of Radon-Related Lung Cancer; Survivors Commit to Risk Reduction Despite Failed Government Policy 2Health News:Program to Identify Likely Victims of Radon-Related Lung Cancer; Survivors Commit to Risk Reduction Despite Failed Government Policy 3Health News:Program to Identify Likely Victims of Radon-Related Lung Cancer; Survivors Commit to Risk Reduction Despite Failed Government Policy 4
... protein 4 (IGFBP-4) is a 24 kDa protein ... IGF-I and IGF-II. It is also present in ... 28 kDa. IGFBP-4 has been identified in all ... types, including fibroblasts, neuroblastoma, prostate and bone cells ...
... the adrenal gland and gonads, is the ... both of which may be subsequently converted ... activity, estimated at ~(less than or equal ... androstenedione levels often exceed testosterone in both ...
... Inhibins are heterodimeric proteins that suppress ... from the pituitary. Inhibin consists of two ... linked together. Inhibin A consists of the ... the alpha-subunit and betaB-subunit. Only the dimeric ...
... a 7.5 kDa peptide which is secreted primarily ... mitogenic and metabolic actions involved in cellular growth. ... to target cell receptors. IGF-II binds with high ... monomeric protein which also serves as the receptor ...
Medicine Products: